Irinotecan

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Camptosar (Pfizer); Onivyde (Merrimack)
  • INDICATIONS:

    Metastatic colorectal carcinoma (Camptosar); metastatic adenocarcinoma of the pancreas (Onivyde - in combination with fluorouracil and leucovorin)

    Advanced pancreatic cancer in combination with oxaliplatin/fluorouracil/leucovorin (FOLFIRINOX or FOLFOXIRI ))

    Used in combination with fluorouracil and leucovorin (FOLFIRI) for treatment of advanced-stage and metastatic colorectal cancer


  • CLASS: Antineoplastic, Topoisomerase 1 inhibitor
  • HALF-LIFE: 6–10 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aprepitant, Atazanavir, Bevacizumab, Ketoconazole, Lapatinib, Safinamide, Sorafenib, St John's Wort, Strong CYP3A4 inhibitors, Voriconazole

PREGNANCY CATEGORY: D

DIARRHEA and MYELOSUPPRESSION (Camptosar)

SEVERE NEUTROPENIA and SEVERE DIARRHEA (Onivyde)


See full prescribing information for complete boxed warnings.

Our database has 92 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 03/24/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top